Schering Corporation

Merck Sharp + Dohme Corp.

Schering-plough Corporation

Deen Tulshian

Ginny Dai Ho

Lisa S Silverman

Julius J Matasi

Bernard R Neustadt

Ana Bercovici

Samuel Chackalamannil

Brian Alexander McKittrick

Duane A Burnett

Wen-Lian Wu

Yan Xia

Francis M Cuss

John A Hey

Richard W Chapman

Peter Korakas

Robbie L McLeod

William J Greenlee

Elizabeth M Smith

Craig D Boyle

Neil A Lindo

Thavalakulamgara K Sasikumar

Martin Domalski

Li Qiang

Eugenia Y Kiselgof

William T McElroy

Ronald J Doll

Michael D Altman

Joey Lee Methot

Brian J Lavey

John P Caldwell

John W Lampe

Michael F Czarniecki

Liang Zhu

Shu-Wei Yang

Zheng Tan

W Michael Seganish

Stephanie Brumfield

Hua Zhou

Joseph A Kozlowski

Wensheng Yu

Jongwon Lim

Sunil Paliwal

Guoqing Li

Craig R Gibeau

Gregory Scott Martin

William Bert Geiss

Joel M Harris

Chad E Bennett

Kallol Basu

Chad E Knutson

Mary Ann Caplen

Hyunjin M Kim

Charles V Magatti

R Jason Herr

David G Sawutz

Fay Ng

Larry Yet

Van-Duc Le

Jinhai Yang

William Michael Seganish

James C Haber, Jr

Stephanie Nicole Cooke

James P Harding, Iii

Philippe Brianceau

Michael Kc Wong

Martin S Domalksi

Martin S Domalski

Sasikumar K Thavalakulamgara

The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Inhibitors of IRAK4 activity

This invention relates to aminopyrimidinone compounds of Formula (I) that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

Aminopyrimidinones as interleukin receptor-associated kinase inhibitors

This invention relates to amidopyrazole compounds that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment of cellular proliferative diseases, for example, cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.

Amidopyrazole inhibitors of interleukin receptor-associated kinases

The present invention relates to substituted triazolopyridines and analogs thereof, the use of the compounds as phosphodiesterase 10 (PDE10) inhibitors for the treatment of PDE10-modulated disorders, to pharmaceutical compositions comprising the compounds.

Substituted triazolopyridines and analogs thereof

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein

Adenosine Areceptor antagonists

The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease.

Polycyclic guanine derivatives and use thereof

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J-J, X, and R-Rare as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease. 

mGluR1 antagonists as therapeutic agents

Compounds of the formula or a pharmaceutically acceptable salt thereof, wherein

3-monosubstituted tropane derivatives as nociceptin receptor ligands

Disclosed are compounds of the formula: and compounds of the formula: wherein R, R, R, R, R, u and v are as defined herein. Also disclosed are methods of treating pain (e.g., inflammatory pain, chronic pain, and neuropathic pain), methods of treating diabetes, and methods of inhibiting the absorption of cholesterol using compounds of formula I or IIA.

Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism

The compound of the formula or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions therefore, and the use of said compounds as nociceptin receptor inhibitors useful in the treatment of anxiety are disclosed.

High affinity ligands for nociceptin receptor ORL-1

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J-J, X, and R&#x2014;Rare as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease. 

Novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein:

Disclosed are compounds having the structural formulaor pharmaceutically acceptable salts or solvates thereof, wherein

Adenosine A2a receptor antagonists

Growing community of inventors

Lebanon, NJ, United States of America

Deen Tulshian